BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
(Reuters) — German drug and farming supplies company Bayer posted a 45% gain in quarterly core earnings thanks to the acquisition of seed-maker Monsanto, while the legal burden it took on with the deal mounted.
Adjusted earnings before interest, tax, depreciation and amortization, or EBITDA, rose to €4.19 billion ($4.67 billion), it said on Thursday, edging past the €4.12 billion average analyst forecast in a Reuters poll.
Bayer said 13,400 plaintiffs were seeking damages, alleging that use of the company’s glyphosate-based weedkillers caused their cancer, up from 11,200 in January.
Bayer has seen about €30 billion ($34 billion) wiped off its market value since August, when a California jury in that lawsuit found that Monsanto should have warned of the alleged cancer risks.
It will face shareholders’ anger at its annual general meeting on Friday.
“We continue to believe that we have meritorious defenses, and we intend to defend ourselves vigorously in all of these lawsuits,” the company said.
On Wednesday, Bayer launched an appeal with a California court to throw out the first glyphosate-related judgment for $78 million in damages.
When including Monsanto’s pro-forma 2018 results in the comparison, revenues at Bayer’s Crop Science division from pesticides and seeds were broadly flat at €6.35 billion, excluding currency effects.
That was above an analyst consensus of €6.13 billion, as the launch of new insecticide products helped offset a decline on soybean seed sales. The shares were indicated 3.3% higher in early Frankfurt floor trading at 0742 GMT.
The company is still aiming for an increase in 2019 EBITDA before special items to about €12.2 billion, excluding the effect of currency swings and the planned sale of assets such as the animal health unit.
Revenues from its bestseller Xarelto, to prevent strokes, and eye drug Eylea both gained more than 15%, to €937 million and €583 million, respectively, beating market expectations.
(Reuters) — Bayer AG’s nonexecutive board reaffirmed its support for top management’s decision to acquire seed-maker Monsanto last year, after losing high-profile lawsuits to U.S. plaintiffs who claimed Monsanto’s Roundup weedkiller caused their cancer.